Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-dampened chemotherapy and photodynamic therapy at a single dose
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Hypoxia is a characteristic feature of solid tumors and an important causation of resistance to chemotherapy and photodynamic therapy (PDT).It is challenging to develop efficient functional nanomaterials for tumor oxygenation and therapeutic applications.Methods: Through disulfide reconfiguration to hybridize hemoglobin and albumin, tumor-targeted hybrid protein oxygen carriers (HPOCs) were fabricated, serving as nanomedicines for precise tumor oxygenation and simultaneous enhancement of hypoxia-dampened chemotherapy and photodynamic therapy.Based on encapsulation of doxorubicin (DOX) and chlorin e6 (Ce6) into HPOCs to form ODC-HPOCs, the mechanism and therapeutic efficacy of oxygen-enhanced chemo-PDT was investigated in vitro and in vivo.Results: The precise oxygen preservation and release of the HPOC guaranteed sufficient tumor oxygenation, which is able to break hypoxia-induced chemoresistance by downregulating the expressions of hypoxia-inducible factor-1α (HIF-1α), multidrug resistance 1 (MDR1) and P-glycoprotein (P-gp), resulting in minimized cellular efflux of chemodrug.Moreover, the oxygen supply is fully exploited for upgrading the generation of reactive oxygen species (ROS) during the photodynamic process.As a result, only a single-dose treatment of the HPOCs-based chemo-PDT exhibited superior tumor suppression.The combination therapy was guided by in vivo fluorescence/photoacoustic imaging with nanoparticle tracking and oxygen monitoring.Conclusion: This well-defined HPOC as a versatile nanosystem is expected to pave a new way for breaking multiple hypoxia-induced therapeutic resistances to achieve highly effective treatment of solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460 · cited 1×
“As suggested in previous reports, tumor chemoresistance is correlated with upregulated HIF-1α, which activates the expressions of MDR1 and P-gp, and mediates the efflux of chemodrugs (such as DOX and cisplatin [45, 46], while Ce6 is not included [47]) from cancer cells.”
BackgroundRetractedTargeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“For instance, hyperbaric oxygen chambers have been clinically utilized to force more oxygen into the blood and the tumor when patients undergo cancer therapies [19-22].”
BackgroundThe Tumour Microenvironment after Radiotherapy: Mechanisms of Resistance and Recurrence
Barker, H. E., Paget, J. T. E., Khan, A. A., & Harrington, K. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3958 · Cited by 2,144 · cited 1×
“For instance, hyperbaric oxygen chambers have been clinically utilized to force more oxygen into the blood and the tumor when patients undergo cancer therapies [19-22].”
BackgroundRouschop, K. M. A., van den Beucken, T., Dubois, L., Niessen, H., Bussink, J., Savelkouls, K., Keulers, T., Mujcic, H., Landuyt, W., Voncken, J. W., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40027 · Cited by 829
Drug-induced oxidative stress and toxicity
Deavall, D. G., Martin, E. A., Horner, J. M., & Roberts, R. (2012) · Journal of Toxicology · doi:10.1155/2012/645460 · Cited by 689 · cited 1×
“In chemotherapy, hypoxic cells are resistant to most anticancer drugs, which require oxygen to increase the cytotoxicity of the DNA lesions [10].”
BackgroundZhu, J.-Y., Zheng, D.-W., Zhang, M.-K., Yu, W.-Y., Qiu, W.-X., Hu, J.-J., Feng, J., & Zhang, X.-Z. (2016) · Nano Letters · doi:10.1021/acs.nanolett.6b02786 · Cited by 498 · cited 1×
“Also, compared to literature reports of chemotherapy with 3 injections [54], or 8-fold DOX content in nanoparticles at one dose [55], chemotherapy of ODC-HPOCs, which was undertaken with a single injection at rather low DOX concentration, also exhibited highly efficient tumor inhibition due to the targeted oxygen supp…”
Huang, C.-C., Chia, W.-T., Chung, M.-F., Lin, K.-J., Hsiao, C.-W., Jin, C., Lim, W.-H., Chen, C.-C., & Sung, H.-W. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b01784 · Cited by 372 · cited 1×
“) [25, 26] and oxygen carriers (perfluorocarbon, hemoglobin (Hb), etc.”
BackgroundThe metabolic fate of acetate in cancer
Schug, Z. T., Vande Voorde, J., & Gottlieb, E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.87 · Cited by 331 · cited 1×
“Effects of hypoxia on tumor biology include tumor angiogenesis, vasculogenesis, invasiveness and metastasis, as well as resistance to therapies through multiple mechanisms [6-9].”
BackgroundHyperbaric oxygen therapy sensitizes nimustine treatment for glioma in mice
Lu, Z., Ma, J., Liu, B., Dai, C., Xie, T., Ma, X., Li, M., Dong, J., Lan, Q., & Huang, Q. (2016) · Cancer Medicine · doi:10.1002/cam4.851 · Cited by 42 · cited 1×
“For instance, hyperbaric oxygen chambers have been clinically utilized to force more oxygen into the blood and the tumor when patients undergo cancer therapies [19-22].”
Background
Cited by
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Controlling the biodistribution and clearance of nanomedicines
Cabral, H., Li, J., Miyata, K., & Kataoka, K. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00138-1 · Cited by 303
“…the efficacy of PDT is limited in hypoxic tumours owing to low oxygen concentration, which results in inadequate ROS generation, several nanomedicines have been developed to increase oxygen levels in tumours by using nanocarriers loaded with haemoglobin, oxygen-producing enzymes or algae 260–263 .”
Tailoring photosensitive ROS for advanced photodynamic therapy
Sai, D. L., Lee, J., Nguyen, D. L., & Kim, Y.-P. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00599-7 · Cited by 275
Sun, Y., Zhao, D., Wang, G., Wang, Y., Cao, L., Sun, J., Jiang, Q., & He, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.004 · Cited by 250
Xu, K., Zhan, Y., Yuan, Z., Qiu, Y., Wang, H., Fan, G., Wang, J., Li, W., Cao, Y., Shen, X., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.017 · Cited by 160
Metadata
- Authors
- Luo, Z., Tian, H., Liu, L., Chen, Z., Liang, R., Chen, Z., Wu, Z., Ma, A., Zheng, M., & Cai, L.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 8
- Issue
- 13
- Pages
- 3584-3596
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2977396639
- Cited by
- 119
- References
- 10
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-dampened chemotherapy and photodynamic therapy at a single dose. https://app.cochat.ai/papers/10.7150/thno.25409
- The paper
- Luo, Z., Tian, H., Liu, L., Chen, Z., Liang, R., Chen, Z., Wu, Z., Ma, A., Zheng, M., & Cai, L. (2018). Tumor-targeted hybrid protein oxygen carrier to simultaneously enhance hypoxia-dampened chemotherapy and photodynamic therapy at a single dose. Theranostics. https://doi.org/10.7150/thno.25409
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.